Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2024DiagnosticsOpen Access

Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection among CYP3A5-Expressing Renal Transplant Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

KSKristina SchönfelderBMBirte MöhlendickUEUte Eisenberger

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Schönfelder et al. (2024) studied this question.

synapsesocial.com/papers/68e55ff7e2b3180350efc8e6https://doi.org/10.3390/diagnostics14192202
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of cytochrome P450 3A5 expression on clinical outcomes in renal transplant recipients receiving tacrolimus-based immunosuppression2025 · 2 citations
  2. 2Cohort Study to Determine the Impact of <i>CYP3A5</i> Genotype on Tacrolimus Dosing Requirements and Trough Concentrations in Heart Transplant Recipients2026
  3. 3B-222 Receptor-donor CYP3A5 and CYP3A4 genotype testing in liver transplant patients and its influence in tacrolimus blood levels: a retrospective study2024
  4. 4Impact of CYP3A5 Gene Polymorphisms on Tacrolimus Pharmacokinetics and Renal Allograft Rejection in Kidney Transplant Recipients: A Meta-Analysis Across Ethnic Populations2025
  5. 5CYP3A5 genotyping-guided dosing versus weight-based dosing in a multi-ethnic population of kidney transplant recipients2025